Merck Mevacor Pediatric Exclusivity To Be Revisited By FDA By July 17
FDA's Pediatric Exclusivity Board is expected to reevaluate the pediatric exclusivity application for Merck's cholesterol drug Mevacor (lovastatin) by July 17.
FDA's Pediatric Exclusivity Board is expected to reevaluate the pediatric exclusivity application for Merck's cholesterol drug Mevacor (lovastatin) by July 17.